Get started
Author

A Perkovic

Observed institution: AbbVie (United States)
OpenAlex ID: A5123530274
Assoziation endoskopischer Ergebnisse mit langfristigen klinischen Verbesserungen bei Patienten mit mittelschwer bis schwer aktivem Morbus Crohn, die mit Upadacitinib behandelt wurden: Ergebnisse aus der U-ENDURE Langzeit-Erweiterungsstudie
2026 · E V Loftus, E Louis, et al. · Zeitschrift für Gastroenterologie
P0774 Long-term sustained improvement of health-related quality of life, work productivity and fatigue in patients with moderately to severely active Crohn’s disease treated with upadacitinib: Results from the U-ENDURE long-term extension study
2026 · J Panés, E Louis, et al. · Journal of Crohn s and Colitis
P1156 Association Between Histologic and Endoscopic Outcomes With Long-Term Clinical and Symptomatic Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis Treated With Upadacitinib
2026 · F Magro, V Jairath, et al. · Journal of Crohn s and Colitis
PDF
P0749 Association of endoscopic outcomes with long-term clinical improvements in patients with moderately to severely active Crohn’s disease treated with upadacitinib: Results from the U-ENDURE long-term extension study
2026 · E Loftus, E Louis, et al. · Journal of Crohn s and Colitis
Works count: 4
Citation count:
H-index:
I10-index:
Year
Topic
Type